Journal profile · Medicine-Oncology
Nature Cancer
ISSN 2662-1347 · Springer Nature · 12 issues per year
Nature Cancer: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 27.97; hybrid open access; APC about USD 12,690; median 351 days to acceptance (52 articles, last 24 months); 204 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Nature Cancer is published by Springer Nature and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics and CAR-T cell therapy research, together about 30.9% of its articles. Its main subfields are Oncology and Immunology. (generated from OpenAlex topic counts and CAS ranking data)
Nature Cancer aims to publish the most significant advances across the full spectrum of cancer research in the life, physical, applied and social sciences, spanning basic preclinical, translational and clinical work. The journal’s broad scope covers all cancer research offering new insights into cancer biology and genetics, new approaches for the development and delivery of diagnostics and therapies, and new ways of understanding the global societal impact of cancer, ensuring that the work published reaches the widest possible audience. For more information please see Aims & Scope.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Oncology
Editor-in-chief Research Cross-JournalPublisher website
Editorial board by country: 1 in mainland China (about 8%); most named United States 5, United Kingdom 2, Germany 2, Mainland China 1, Italy 1 (12 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Immunotherapy and BiomarkersMedicine11.6%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology10.5%
- CAR-T cell therapy researchMedicine8.9%
- Immunotherapy and Immune ResponsesImmunology and Microbiology8.1%
- Immune Cell Function and InteractionImmunology and Microbiology5.4%
- Immune cells in cancerImmunology and Microbiology5.2%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology4.8%
- Cancer Cells and MetastasisMedicine4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Oncology | Zone 1 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of SciencePublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 27.97LetPub ·
- Impact factor (publisher) 2025
- 28Publisher website ·
- 5-year impact factor (publisher) 2025
- 31.2Publisher website ·
- CiteScore 2026-06
- 38.5LetPub ·
- SJR 2026-06
- 12.44LetPub ·
- SNIP 2026-06
- 4.6LetPub ·
- h-index
- 134OpenAlex ·
- i10-index
- 615OpenAlex ·
- 2-year mean citedness
- 17.47OpenAlex ·
- Self-citation rate
- 0.7%LetPub ·
- Share of gold OA articles
- 38.56%LetPub ·
Volume
- Articles per year
- 117LetPub ·
- Downloads per year (publisher) 2025
- 3,054,854Publisher website ·
Articles by year OpenAlex count · 1,237 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 157 | 61 | 385 |
| 2025 | 204 | 84 | 3,192 |
| 2024 | 194 | 92 | 6,121 |
| 2023 | 177 | 92 | 8,185 |
| 2022 | 183 | 98 | 14,094 |
| 2021 | 161 | 89 | 13,932 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
351 daysMedian, submission to acceptance · P25–P75 260 days – 479 days
- Acceptance to online
- median 38 days (52 articles)
- Submission to online
- median 393 days
- Sample
- 52 articles with submission and acceptance dates (410 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Peer review
- Double anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 12,690 / EUR 10,690 / GBP 9,190 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websitePeer review
- Peer review 3 – Editorial Process, Peer Review, Appeals & Transfers
Once you have submitted your manuscript, it goes through our editorial process. If your manuscript is sent out for peer review, you will receive an email asking you to read and sign our Editorial Policies. To appeal against a decision, or transfer your submission to another journal – Appeals and Transfers. ____________________________________________________________________________________________…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Frequency
- 12 issues per year
- ISSN
- 2662-1347
- Official links
- Journal homepage ↗LetPub
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Nature Cancer
What CAS zone is Nature Cancer in?
In the 2025 upgraded edition of the CAS Journal Ranking, Nature Cancer is in Zone 1 of Medicine, and in Zone 1 of the minor category Oncology; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Nature Cancer?
The latest impact factor listed by LetPub is 27.97; CiteScore 38.5, h-index 134.
How long does peer review take at Nature Cancer?
Based on the dates recorded on 52 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 351 days (interquartile range 260–479 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Nature Cancer based?
Of the 12 board members whose country the journal's board page names, 1 (about 8%) are in mainland China; the countries named most often are United States (5), United Kingdom (2) and Germany (2). Counted from the institutions listed on the board page; for reference only.
Which databases index Nature Cancer?
According to LetPub and DOAJ records, Nature Cancer is indexed in SCIE and Scopus. The journal's website also lists Web of Science; that list has not been checked against each database.
Is Nature Cancer open access, and what is the APC?
Nature Cancer is a hybrid journal. For open-access publication: APC about USD 12,690.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .